PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 24, 1988JAMA374 citations

Adjuvant Therapy of Colorectal Cancer

View Full Paper
MBMarc Buyse

Key Points

  • To evaluate the impact of adjuvant radiotherapy and chemotherapy on overall survival in patients with colorectal cancer across published randomized controlled trials.
  • Identified and reviewed all English-language randomized controlled trials of adjuvant colorectal cancer therapy published up to December 1986.
  • Analyzed 8 trials comparing radiotherapy with control in rectal cancer (N=3,062) and 17 trials comparing chemotherapy with control in colorectal cancer (N=6,791).
  • Combined survival outcomes across trials testing radiotherapy or chemotherapy interventions using meta-analytic pooling.
  • Fluorouracil-containing adjuvant chemotherapy regimens conferred a statistically significant survival benefit, with a mortality odds ratio of 0.83 (95% CI, 0.70 to 0.98) in favor of therapy.
  • Other chemotherapy and radiotherapy combinations showed no statistically significant differences in overall survival versus control, though mortality odds trended slightly lower in treated patients, especially those with rectal tumors.

Abstract

All randomized controlled trials of adjuvant therapy of colorectal cancer, published up to December 1986 in English, were reviewed. Eight trials compared radiotherapy groups with control groups in rectal cancer (3062 patients), and 17 trials compared chemotherapy groups with control groups in colorectal cancer (6791 patients). The results of trials testing radiotherapy or chemotherapy were combined. Fluorouracil-containing regimens resulted in a small benefit of therapy in terms of overall survival, with a mortality odds ratio of 0.83 in favor of therapy (95% confidence interval, 0.70 to 0.98). All other combinations of trials failed to show statistically significant differences between treated and control patients, even though the odds of death tended to be slightly lower in treated patients, especially those with rectal tumors. Some overall survival benefit from adjuvant therapy cannot be excluded, but it is likely small. Such small benefit, if real, would be far from negligible in a common case of malignancy with long survival expectancy. Trials much larger than those published up to now are needed.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Marc Buyse (1988) studied this question.

synapsesocial.com/papers/6a12f8f945487b7639a7781chttps://doi.org/10.1001/jama.1988.03720240033031
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination of neoadjuvant and adjuvant chemotherapy with FOLFOX compared with adjuvant chemotherapy in management of locally advanced rectal cancers: a randomized trial of a promising therapeutic approach2024 · 2 citations
  2. 2Efficacy of Adjuvant Chemotherapy for T1-2 Stage III Colorectal Cancer2025
  3. 3Impact of Adjuvant Chemotherapy on the Prognosis in Elderly Patients with Stage II and III Colorectal Cancer: A Retrospective Multicenter Study2026
  4. 4Comparative Effectiveness of Adjuvant Therapy on Survival in Patients With Metastatic Colorectal Cancer2024
  5. 5Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?2024 · 3 citations